Share Price and Basic Stock Data
Last Updated: February 14, 2026, 8:29 pm
| PEG Ratio | -1.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bodal Chemicals Ltd operates in the Dyes & Pigments industry, with a current stock price of ₹51.3 and a market capitalization of ₹647 Cr. The company reported a trailing twelve-month (TTM) revenue of ₹1,829 Cr, reflecting a growth from ₹1,574 Cr in FY 2023 and ₹1,395 Cr in FY 2024. Quarterly revenues showed variability, with sales reaching ₹401.22 Cr in September 2022, declining to ₹320.73 Cr in December 2022, and then fluctuating between ₹330 Cr and ₹450 Cr in subsequent quarters. The highest quarterly revenue recorded was ₹480.45 Cr in September 2025. Such fluctuations suggest a cyclical nature in demand or potential operational inefficiencies. The operating profit margin (OPM) stood at a modest 4.79%, indicating potential room for improvement in cost management relative to industry benchmarks. The company’s ability to stabilize and grow revenue will be crucial in maintaining its market position in an increasingly competitive environment.
Profitability and Efficiency Metrics
Bodal Chemicals recorded a net profit of ₹35 Cr, translating to a low return on equity (ROE) of 2.51% and return on capital employed (ROCE) of 5.51%. These figures reflect challenges in generating returns for shareholders compared to industry averages. The company’s operating profit varied, peaking at ₹47.61 Cr in June 2025 but declining to ₹22.99 Cr by September 2025, showcasing inconsistent profitability. The interest coverage ratio (ICR) of 2.09x indicates that while the company can cover its interest expenses, the margin is thin, posing a risk if revenues decline further. The cash conversion cycle (CCC) is reported at 125 days, which is relatively high, suggesting inefficiencies in inventory and receivables management. Overall, while Bodal Chemicals has demonstrated some capacity for profit generation, the metrics indicate significant operational challenges that need addressing to enhance profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Bodal Chemicals reveals total assets of ₹2,313 Cr, against total borrowings of ₹866 Cr, indicating a debt-to-equity ratio of approximately 0.81x. This level of leverage is moderate and reflects a strategy of utilizing debt to finance growth. Reserves stood at ₹1,097 Cr, providing a cushion for financial stability. However, the company’s current ratio is 1.17, which is on the lower side of the ideal range of 1.5 to 2, indicating potential liquidity concerns. The price-to-book value (P/BV) ratio is notably low at 0.66x, suggesting that the stock is undervalued relative to its book value, which could attract value investors. The company’s ability to manage its liabilities effectively while maintaining a healthy balance sheet will be critical in navigating market uncertainties and funding future growth initiatives.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bodal Chemicals indicates a strong promoter holding of 57%, which reflects management confidence in the company’s future. However, foreign institutional investors (FIIs) hold a mere 0.29%, and domestic institutional investors (DIIs) have no stake, suggesting limited institutional interest. The public holds 42.70% of the shares, which indicates a diverse retail investor base. The number of shareholders has increased from 64,225 in December 2022 to 74,649 as of September 2025, reflecting growing retail participation. This increase could signal rising investor confidence, though the lack of institutional backing may limit capital inflow and market credibility. The trends in shareholding patterns suggest a need for the company to enhance its engagement with institutional investors to bolster confidence and attract larger investments.
Outlook, Risks, and Final Insight
The outlook for Bodal Chemicals appears cautiously optimistic, contingent upon improving operational efficiencies and stabilizing revenue streams. Key strengths include a strong promoter holding and a relatively low P/BV ratio, which may attract value investors. However, the company faces risks such as inconsistent profitability, a high cash conversion cycle, and limited institutional investor interest, which could hinder capital access and growth potential. Addressing operational inefficiencies, particularly in inventory management and receivables, will be essential for enhancing profitability. Additionally, fostering relationships with institutional investors could provide the necessary support for future expansion. The company must navigate these challenges effectively to capitalize on market opportunities and sustain long-term growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dynamic Industries Ltd | 35.2 Cr. | 116 | 190/68.5 | 18.8 | 162 | 0.86 % | 5.68 % | 3.39 % | 10.0 |
| Daikaffil Chemicals India Ltd | 29.4 Cr. | 49.0 | 214/48.3 | 13.2 | 0.00 % | 18.6 % | 18.6 % | 10.0 | |
| Amal Ltd | 677 Cr. | 548 | 1,148/450 | 24.8 | 91.7 | 0.18 % | 36.3 % | 35.0 % | 10.0 |
| Vidhi Specialty Food Ingredients Ltd | 1,569 Cr. | 314 | 483/272 | 32.8 | 62.2 | 1.59 % | 18.7 % | 14.9 % | 1.00 |
| Ushanti Colour Chem Ltd | 78.5 Cr. | 69.9 | 70.0/38.0 | 37.7 | 0.00 % | 0.98 % | 5.98 % | 10.0 | |
| Industry Average | 1,219.23 Cr | 271.92 | 193.33 | 186.93 | 0.42% | 10.89% | 9.02% | 8.13 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401.22 | 320.73 | 389.58 | 332.49 | 330.00 | 338.55 | 393.59 | 421.96 | 428.63 | 443.47 | 450.87 | 454.20 | 480.45 |
| Expenses | 369.13 | 296.18 | 362.67 | 310.28 | 306.51 | 314.68 | 368.48 | 387.50 | 395.97 | 398.97 | 403.61 | 406.59 | 457.46 |
| Operating Profit | 32.09 | 24.55 | 26.91 | 22.21 | 23.49 | 23.87 | 25.11 | 34.46 | 32.66 | 44.50 | 47.26 | 47.61 | 22.99 |
| OPM % | 8.00% | 7.65% | 6.91% | 6.68% | 7.12% | 7.05% | 6.38% | 8.17% | 7.62% | 10.03% | 10.48% | 10.48% | 4.79% |
| Other Income | 1.69 | 2.22 | 3.89 | 8.78 | 5.93 | 4.65 | 5.45 | 2.46 | 5.07 | 0.65 | 2.35 | 4.05 | 19.90 |
| Interest | 7.26 | 10.11 | 11.58 | 13.15 | 13.42 | 12.09 | 15.60 | 21.33 | 19.54 | 19.71 | 21.00 | 21.63 | 19.92 |
| Depreciation | 12.19 | 13.92 | 14.65 | 14.65 | 14.31 | 14.52 | 17.01 | 17.03 | 17.20 | 17.26 | 17.01 | 17.51 | 17.42 |
| Profit before tax | 14.33 | 2.74 | 4.57 | 3.19 | 1.69 | 1.91 | -2.05 | -1.44 | 0.99 | 8.18 | 11.60 | 12.52 | 5.55 |
| Tax % | 28.33% | 11.31% | 38.51% | 30.72% | 26.04% | 49.21% | -200.00% | -18.75% | 124.24% | 33.74% | -25.09% | 23.88% | -7.93% |
| Net Profit | 10.27 | 2.43 | 2.81 | 2.21 | 1.24 | 0.98 | 2.04 | -1.18 | -0.24 | 5.42 | 14.50 | 9.53 | 5.99 |
| EPS in Rs | 0.84 | 0.19 | 0.22 | 0.18 | 0.10 | 0.08 | 0.16 | -0.09 | -0.02 | 0.43 | 1.15 | 0.76 | 0.48 |
Last Updated: January 2, 2026, 5:01 am
Below is a detailed analysis of the quarterly data for Bodal Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 480.45 Cr.. The value appears strong and on an upward trend. It has increased from 454.20 Cr. (Jun 2025) to 480.45 Cr., marking an increase of 26.25 Cr..
- For Expenses, as of Sep 2025, the value is 457.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 406.59 Cr. (Jun 2025) to 457.46 Cr., marking an increase of 50.87 Cr..
- For Operating Profit, as of Sep 2025, the value is 22.99 Cr.. The value appears to be declining and may need further review. It has decreased from 47.61 Cr. (Jun 2025) to 22.99 Cr., marking a decrease of 24.62 Cr..
- For OPM %, as of Sep 2025, the value is 4.79%. The value appears to be declining and may need further review. It has decreased from 10.48% (Jun 2025) to 4.79%, marking a decrease of 5.69%.
- For Other Income, as of Sep 2025, the value is 19.90 Cr.. The value appears strong and on an upward trend. It has increased from 4.05 Cr. (Jun 2025) to 19.90 Cr., marking an increase of 15.85 Cr..
- For Interest, as of Sep 2025, the value is 19.92 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 21.63 Cr. (Jun 2025) to 19.92 Cr., marking a decrease of 1.71 Cr..
- For Depreciation, as of Sep 2025, the value is 17.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.51 Cr. (Jun 2025) to 17.42 Cr., marking a decrease of 0.09 Cr..
- For Profit before tax, as of Sep 2025, the value is 5.55 Cr.. The value appears to be declining and may need further review. It has decreased from 12.52 Cr. (Jun 2025) to 5.55 Cr., marking a decrease of 6.97 Cr..
- For Tax %, as of Sep 2025, the value is -7.93%. The value appears to be improving (decreasing) as expected. It has decreased from 23.88% (Jun 2025) to -7.93%, marking a decrease of 31.81%.
- For Net Profit, as of Sep 2025, the value is 5.99 Cr.. The value appears to be declining and may need further review. It has decreased from 9.53 Cr. (Jun 2025) to 5.99 Cr., marking a decrease of 3.54 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.48. The value appears to be declining and may need further review. It has decreased from 0.76 (Jun 2025) to 0.48, marking a decrease of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 960 | 1,043 | 908 | 1,233 | 1,142 | 1,424 | 1,375 | 1,226 | 2,055 | 1,574 | 1,395 | 1,745 | 1,829 |
| Expenses | 770 | 859 | 758 | 1,007 | 946 | 1,187 | 1,237 | 1,140 | 1,835 | 1,441 | 1,284 | 1,578 | 1,667 |
| Operating Profit | 189 | 184 | 150 | 226 | 196 | 236 | 138 | 87 | 220 | 133 | 111 | 167 | 162 |
| OPM % | 20% | 18% | 16% | 18% | 17% | 17% | 10% | 7% | 11% | 8% | 8% | 10% | 9% |
| Other Income | -70 | 5 | 19 | 15 | 8 | 13 | 10 | 16 | -2 | 12 | 9 | 2 | 27 |
| Interest | 47 | 27 | 12 | 9 | 5 | 9 | 19 | 17 | 29 | 41 | 54 | 82 | 82 |
| Depreciation | 25 | 22 | 26 | 29 | 12 | 21 | 28 | 30 | 47 | 53 | 60 | 69 | 69 |
| Profit before tax | 47 | 139 | 131 | 204 | 186 | 219 | 101 | 55 | 142 | 51 | 5 | 19 | 38 |
| Tax % | 35% | 34% | 34% | 35% | 33% | 35% | 15% | 28% | 31% | 25% | -37% | 4% | |
| Net Profit | 30 | 92 | 86 | 133 | 122 | 141 | 86 | 40 | 99 | 38 | 6 | 18 | 35 |
| EPS in Rs | 2.76 | 8.41 | 7.88 | 12.18 | 10.03 | 11.72 | 7.12 | 3.43 | 8.51 | 3.03 | 0.51 | 1.47 | 2.82 |
| Dividend Payout % | 0% | 0% | 8% | 7% | 8% | 7% | 11% | 23% | 9% | 3% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 206.67% | -6.52% | 54.65% | -8.27% | 15.57% | -39.01% | -53.49% | 147.50% | -61.62% | -84.21% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -213.19% | 61.17% | -62.92% | 23.84% | -54.58% | -14.48% | 200.99% | -209.12% | -22.59% | 284.21% |
Bodal Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -14% |
| 5 Years: | -26% |
| 3 Years: | -45% |
| TTM: | 875% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -2% |
| 3 Years: | -13% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 4% |
| 3 Years: | 2% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:10 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | 25 | 25 |
| Reserves | 43 | 135 | 213 | 341 | 673 | 805 | 907 | 957 | 1,028 | 1,053 | 1,057 | 1,080 | 1,097 |
| Borrowings | 397 | 234 | 143 | 151 | 181 | 171 | 257 | 454 | 676 | 760 | 904 | 911 | 866 |
| Other Liabilities | 131 | 144 | 132 | 193 | 194 | 290 | 267 | 314 | 385 | 283 | 294 | 324 | 325 |
| Total Liabilities | 593 | 534 | 510 | 707 | 1,072 | 1,290 | 1,455 | 1,749 | 2,113 | 2,120 | 2,281 | 2,339 | 2,313 |
| Fixed Assets | 168 | 190 | 192 | 222 | 437 | 609 | 656 | 804 | 817 | 967 | 1,314 | 1,301 | 1,278 |
| CWIP | 9 | 3 | 0 | 9 | 19 | 26 | 7 | 14 | 70 | 193 | 68 | 61 | 61 |
| Investments | 1 | 2 | 2 | 17 | 17 | 6 | 3 | 6 | 0 | 0 | 13 | 0 | 0 |
| Other Assets | 415 | 339 | 316 | 459 | 599 | 650 | 789 | 924 | 1,227 | 960 | 886 | 977 | 973 |
| Total Assets | 593 | 534 | 510 | 707 | 1,072 | 1,290 | 1,455 | 1,749 | 2,113 | 2,120 | 2,281 | 2,339 | 2,313 |
Below is a detailed analysis of the balance sheet data for Bodal Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,097.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,080.00 Cr. (Mar 2025) to 1,097.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 866.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 911.00 Cr. (Mar 2025) to 866.00 Cr., marking a decrease of 45.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 325.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 324.00 Cr. (Mar 2025) to 325.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,313.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,339.00 Cr. (Mar 2025) to 2,313.00 Cr., marking a decrease of 26.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,278.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,301.00 Cr. (Mar 2025) to 1,278.00 Cr., marking a decrease of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 61.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 61.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 973.00 Cr.. The value appears to be declining and may need further review. It has decreased from 977.00 Cr. (Mar 2025) to 973.00 Cr., marking a decrease of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,313.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,339.00 Cr. (Mar 2025) to 2,313.00 Cr., marking a decrease of 26.00 Cr..
Notably, the Reserves (1,097.00 Cr.) exceed the Borrowings (866.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -208.00 | -50.00 | 7.00 | 75.00 | 15.00 | 65.00 | -119.00 | -367.00 | -456.00 | -627.00 | -793.00 | -744.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 69 | 67 | 56 | 91 | 85 | 121 | 139 | 105 | 97 | 100 | 83 |
| Inventory Days | 72 | 43 | 57 | 60 | 59 | 86 | 91 | 141 | 141 | 119 | 139 | 139 |
| Days Payable | 66 | 62 | 67 | 73 | 79 | 91 | 87 | 102 | 81 | 72 | 102 | 97 |
| Cash Conversion Cycle | 92 | 50 | 58 | 43 | 71 | 79 | 124 | 178 | 165 | 144 | 137 | 125 |
| Working Capital Days | 41 | 23 | 18 | 21 | 58 | 50 | 65 | 73 | 55 | 49 | 19 | 20 |
| ROCE % | 39% | 39% | 35% | 46% | 27% | 24% | 11% | 5% | 12% | 5% | 3% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.25 |
| Diluted EPS (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.24 |
| Cash EPS (Rs.) | 6.91 | 5.32 | 7.25 | 11.86 | 5.74 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 87.72 | 86.04 | 85.79 | 85.92 | 80.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 87.72 | 86.04 | 85.79 | 85.92 | 80.10 |
| Revenue From Operations / Share (Rs.) | 138.55 | 110.87 | 125.32 | 167.42 | 100.26 |
| PBDIT / Share (Rs.) | 13.55 | 9.50 | 11.54 | 19.34 | 8.38 |
| PBIT / Share (Rs.) | 8.11 | 4.69 | 7.31 | 15.54 | 5.89 |
| PBT / Share (Rs.) | 1.53 | 0.37 | 4.05 | 11.60 | 4.53 |
| Net Profit / Share (Rs.) | 1.47 | 0.51 | 3.03 | 8.06 | 3.25 |
| NP After MI And SOA / Share (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.43 |
| PBDIT Margin (%) | 9.77 | 8.56 | 9.20 | 11.55 | 8.35 |
| PBIT Margin (%) | 5.85 | 4.22 | 5.83 | 9.28 | 5.87 |
| PBT Margin (%) | 1.10 | 0.33 | 3.22 | 6.92 | 4.51 |
| Net Profit Margin (%) | 1.06 | 0.46 | 2.41 | 4.81 | 3.24 |
| NP After MI And SOA Margin (%) | 1.06 | 0.46 | 2.41 | 5.25 | 3.42 |
| Return on Networth / Equity (%) | 1.67 | 0.59 | 3.52 | 10.19 | 4.30 |
| Return on Capital Employeed (%) | 6.43 | 3.70 | 6.12 | 14.44 | 6.33 |
| Return On Assets (%) | 0.78 | 0.28 | 1.79 | 5.07 | 2.40 |
| Long Term Debt / Equity (X) | 0.36 | 0.40 | 0.33 | 0.20 | 0.10 |
| Total Debt / Equity (X) | 0.81 | 0.82 | 0.70 | 0.54 | 0.35 |
| Asset Turnover Ratio (%) | 0.75 | 0.63 | 0.74 | 0.96 | 0.71 |
| Current Ratio (X) | 1.17 | 1.17 | 1.37 | 1.41 | 1.43 |
| Quick Ratio (X) | 0.73 | 0.78 | 0.89 | 0.85 | 0.92 |
| Inventory Turnover Ratio (X) | 5.77 | 4.98 | 2.24 | 3.10 | 3.25 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 19.44 | 25.79 | 9.10 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 1.87 | 10.76 | 6.35 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 80.56 | 74.21 | 90.90 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 98.13 | 89.24 | 93.65 | 0.00 |
| Interest Coverage Ratio (X) | 2.09 | 2.20 | 3.53 | 8.04 | 6.16 |
| Interest Coverage Ratio (Post Tax) (X) | 1.24 | 1.12 | 1.93 | 4.98 | 3.39 |
| Enterprise Value (Cr.) | 1607.20 | 1786.11 | 1466.28 | 1791.70 | 1436.56 |
| EV / Net Operating Revenue (X) | 0.92 | 1.28 | 0.93 | 0.87 | 1.17 |
| EV / EBITDA (X) | 9.42 | 14.95 | 10.12 | 7.56 | 14.01 |
| MarketCap / Net Operating Revenue (X) | 0.42 | 0.66 | 0.46 | 0.60 | 0.89 |
| Retention Ratios (%) | 0.00 | 80.55 | 74.20 | 90.89 | 0.00 |
| Price / BV (X) | 0.66 | 0.85 | 0.67 | 1.17 | 1.13 |
| Price / Net Operating Revenue (X) | 0.42 | 0.66 | 0.46 | 0.60 | 0.89 |
| EarningsYield | 0.02 | 0.01 | 0.05 | 0.08 | 0.03 |
After reviewing the key financial ratios for Bodal Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 6.91. This value is within the healthy range. It has increased from 5.32 (Mar 24) to 6.91, marking an increase of 1.59.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 87.72. It has increased from 86.04 (Mar 24) to 87.72, marking an increase of 1.68.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 87.72. It has increased from 86.04 (Mar 24) to 87.72, marking an increase of 1.68.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 138.55. It has increased from 110.87 (Mar 24) to 138.55, marking an increase of 27.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.55. This value is within the healthy range. It has increased from 9.50 (Mar 24) to 13.55, marking an increase of 4.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.11. This value is within the healthy range. It has increased from 4.69 (Mar 24) to 8.11, marking an increase of 3.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.37 (Mar 24) to 1.53, marking an increase of 1.16.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 2. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 2. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For PBDIT Margin (%), as of Mar 25, the value is 9.77. This value is below the healthy minimum of 10. It has increased from 8.56 (Mar 24) to 9.77, marking an increase of 1.21.
- For PBIT Margin (%), as of Mar 25, the value is 5.85. This value is below the healthy minimum of 10. It has increased from 4.22 (Mar 24) to 5.85, marking an increase of 1.63.
- For PBT Margin (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 10. It has increased from 0.33 (Mar 24) to 1.10, marking an increase of 0.77.
- For Net Profit Margin (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has increased from 0.46 (Mar 24) to 1.06, marking an increase of 0.60.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 8. It has increased from 0.46 (Mar 24) to 1.06, marking an increase of 0.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.67. This value is below the healthy minimum of 15. It has increased from 0.59 (Mar 24) to 1.67, marking an increase of 1.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 10. It has increased from 3.70 (Mar 24) to 6.43, marking an increase of 2.73.
- For Return On Assets (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has increased from 0.28 (Mar 24) to 0.78, marking an increase of 0.50.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.36, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.81. This value is within the healthy range. It has decreased from 0.82 (Mar 24) to 0.81, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.63 (Mar 24) to 0.75, marking an increase of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 1.17.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.73, marking a decrease of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.77. This value is within the healthy range. It has increased from 4.98 (Mar 24) to 5.77, marking an increase of 0.79.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 19.44 (Mar 24) to 0.00, marking a decrease of 19.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.87 (Mar 24) to 0.00, marking a decrease of 1.87.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 80.56 (Mar 24) to 0.00, marking a decrease of 80.56.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.13 (Mar 24) to 0.00, marking a decrease of 98.13.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 2.20 (Mar 24) to 2.09, marking a decrease of 0.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 3. It has increased from 1.12 (Mar 24) to 1.24, marking an increase of 0.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,607.20. It has decreased from 1,786.11 (Mar 24) to 1,607.20, marking a decrease of 178.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.28 (Mar 24) to 0.92, marking a decrease of 0.36.
- For EV / EBITDA (X), as of Mar 25, the value is 9.42. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 9.42, marking a decrease of 5.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 24) to 0.42, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 80.55 (Mar 24) to 0.00, marking a decrease of 80.55.
- For Price / BV (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.66, marking a decrease of 0.19.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 24) to 0.42, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bodal Chemicals Ltd:
- Net Profit Margin: 1.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.43% (Industry Average ROCE: 10.89%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.67% (Industry Average ROE: 9.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.7 (Industry average Stock P/E: 193.33)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.81
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.06%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Dyes & Pigments | Bodal Corporate House, Beside Maple Green Residency, Ahmedabad Gujarat 380059 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh J Patel | Chairman & Managing Director |
| Mr. Bhavin S Patel | Executive Director |
| Mr. Ankit S Patel | Executive Director |
| Mr. Rohit Maloo | Independent Director |
| Mr. Nalin Kumar | Independent Director |
| Mrs. Neha Huddar | Independent Director |
| Mr. Mayank K Mehta | Independent Director |
| Mr. Rajarshi Gosh | Director |
FAQ
What is the intrinsic value of Bodal Chemicals Ltd?
Bodal Chemicals Ltd's intrinsic value (as of 14 February 2026) is ₹30.29 which is 39.18% lower the current market price of ₹49.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹627 Cr. market cap, FY2025-2026 high/low of ₹81.5/45.4, reserves of ₹1,097 Cr, and liabilities of ₹2,313 Cr.
What is the Market Cap of Bodal Chemicals Ltd?
The Market Cap of Bodal Chemicals Ltd is 627 Cr..
What is the current Stock Price of Bodal Chemicals Ltd as on 14 February 2026?
The current stock price of Bodal Chemicals Ltd as on 14 February 2026 is ₹49.8.
What is the High / Low of Bodal Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bodal Chemicals Ltd stocks is ₹81.5/45.4.
What is the Stock P/E of Bodal Chemicals Ltd?
The Stock P/E of Bodal Chemicals Ltd is 20.7.
What is the Book Value of Bodal Chemicals Ltd?
The Book Value of Bodal Chemicals Ltd is 89.1.
What is the Dividend Yield of Bodal Chemicals Ltd?
The Dividend Yield of Bodal Chemicals Ltd is 0.00 %.
What is the ROCE of Bodal Chemicals Ltd?
The ROCE of Bodal Chemicals Ltd is 5.51 %.
What is the ROE of Bodal Chemicals Ltd?
The ROE of Bodal Chemicals Ltd is 2.51 %.
What is the Face Value of Bodal Chemicals Ltd?
The Face Value of Bodal Chemicals Ltd is 2.00.